CSPC Pharmaceutical Group Stock Price, News & Analysis (OTCMKTS:CHPTY)

$101.08 0.00 (0.00 %)
(As of 12/13/2017 04:00 PM ET)
Previous Close$101.08
Today's Range$101.08 - $101.08
52-Week Range$51.99 - $104.77
VolumeN/A
Average Volume40 shs
Market Capitalization$12.62 billion
P/E Ratio39.79
Dividend Yield0.74%
Beta1.31

About CSPC Pharmaceutical Group (OTCMKTS:CHPTY)

CSPC Pharmaceutical Group logoCSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

Receive CHPTY News and Ratings via Email

Sign-up to receive the latest news and ratings for CHPTY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:CHPTY
CUSIPN/A
Phone+86-311-87037015

Debt

Debt-to-Equity Ratio0.02%
Current Ratio1.95%
Quick Ratio1.44%

Price-To-Earnings

Trailing P/E Ratio39.79
Forward P/E Ratio35.10
P/E Growth1.21

Sales & Book Value

Annual Sales$1.59 billion
Price / Sales7.92
Cash Flow$2.86 per share
Price / Cash35.33
Book Value$10.84 per share
Price / Book9.32

Profitability

Trailing EPSN/A
Net Income$270.58 million
Net Margins17.74%
Return on Equity22.35%
Return on Assets15.16%

Miscellaneous

Employees10,023
Outstanding Shares124,860,000

CSPC Pharmaceutical Group (OTCMKTS:CHPTY) Frequently Asked Questions

What is CSPC Pharmaceutical Group's stock symbol?

CSPC Pharmaceutical Group trades on the OTCMKTS under the ticker symbol "CHPTY."

Who are some of CSPC Pharmaceutical Group's key competitors?

Who are CSPC Pharmaceutical Group's key executives?

CSPC Pharmaceutical Group's management team includes the folowing people:

  • Dongchen Cai, Executive Chairman of the Board, Chief Executive Officer (Age 63)
  • Weidong Pan, Executive Vice Chairman of the Board (Age 47)
  • Kin Man Chak, Executive Director (Age 51)
  • Hua Lu, Executive Director (Age 45)
  • Jianmin Lu, Executive Director (Age 58)
  • Huaiyu Wang, Executive Director (Age 53)
  • Jinxu Wang, Executive Director (Age 46)
  • Zhenguo Wang, Executive Director (Age 47)
  • Ka Sze Lee, Company Secretary, Non-Executive Director (Age 57)
  • Siu Keung Chan, Independent Non-Executive Director (Age 59)

How do I buy CSPC Pharmaceutical Group stock?

Shares of CSPC Pharmaceutical Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CSPC Pharmaceutical Group's stock price today?

One share of CSPC Pharmaceutical Group stock can currently be purchased for approximately $101.08.

How big of a company is CSPC Pharmaceutical Group?

CSPC Pharmaceutical Group has a market capitalization of $12.62 billion and generates $1.59 billion in revenue each year. CSPC Pharmaceutical Group employs 10,023 workers across the globe.

How can I contact CSPC Pharmaceutical Group?

CSPC Pharmaceutical Group's mailing address is No. 226 Huanghe Avenue, SHIJIAZHUANG, HEB 050035, China. The company can be reached via phone at +86-311-87037015 or via email at [email protected]


MarketBeat Community Rating for CSPC Pharmaceutical Group (CHPTY)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about CSPC Pharmaceutical Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CSPC Pharmaceutical Group (OTCMKTS:CHPTY) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for CSPC Pharmaceutical Group (OTCMKTS:CHPTY)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

CSPC Pharmaceutical Group (OTCMKTS:CHPTY) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171$0.77$0.77$0.77
Q4 20171$0.77$0.77$0.77
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CSPC Pharmaceutical Group (OTCMKTS:CHPTY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CSPC Pharmaceutical Group (OTCMKTS CHPTY)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

CSPC Pharmaceutical Group (OTCMKTS CHPTY) News Headlines

Source:
DateHeadline
CSPC Pharmaceutical Group Ltd. (CHPTY) Expected to Earn Q3 2017 Earnings of $0.77 Per ShareCSPC Pharmaceutical Group Ltd. (CHPTY) Expected to Earn Q3 2017 Earnings of $0.77 Per Share
www.americanbankingnews.com - November 17 at 7:10 PM
Zacks Investment Research Upgrades CSPC Pharmaceutical Group Ltd. (CHPTY) to HoldZacks Investment Research Upgrades CSPC Pharmaceutical Group Ltd. (CHPTY) to Hold
www.americanbankingnews.com - November 16 at 8:24 PM

SEC Filings

CSPC Pharmaceutical Group (OTCMKTS:CHPTY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

CSPC Pharmaceutical Group (OTCMKTS CHPTY) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.